Is use of Xanax (alprazolam) associated with liver cancer?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 28, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Is Xanax (Alprazolam) Associated with Liver Cancer?

No, there is no evidence linking Xanax (alprazolam) use to liver cancer. The available research and clinical guidelines do not identify benzodiazepines, including alprazolam, as hepatotoxic agents or carcinogens affecting the liver.

Evidence from Hepatotoxicity Studies

  • A comprehensive study of 201 benzodiazepine mono-abusers taking high doses (average 307 mg diazepam-equivalents daily for 7 years) found no significant drug-induced liver injury, with no patients showing clinically meaningful elevations in transaminases, alkaline phosphatase, or bilirubin 1

  • Benzodiazepines are not listed among occupational or environmental hepatotoxic chemicals associated with liver cancer in the European Association for the Study of the Liver guidelines on occupational liver diseases 2

Pharmacokinetic Considerations in Liver Disease

  • While alprazolam metabolism is slowed in patients with existing alcoholic liver disease (elimination half-life increases from 11.4 to 19.7 hours, and clearance decreases from 1.2 to 0.6 ml/min/kg), this reflects altered drug handling rather than hepatotoxicity 3

  • Alprazolam clearance is reduced in cirrhotic patients, requiring dose adjustments, but this is a consequence of impaired hepatic function rather than evidence of drug-induced liver damage 4

Important Clinical Distinctions

  • The primary concern with benzodiazepines in liver disease is precipitation or worsening of hepatic encephalopathy, not hepatotoxicity or carcinogenesis 5

  • Clinical guidelines recommend avoiding benzodiazepines in patients with liver impairment due to their deleterious effects on mental status and encephalopathy risk, not because of cancer or direct liver toxicity 5

Contrast with Known Hepatotoxic Agents

  • Established occupational liver carcinogens include vinyl chloride monomer (causing hepatocellular carcinoma and angiosarcoma), certain pesticides, and industrial solvents—none of which are benzodiazepines 2

  • NSAIDs, in contrast to benzodiazepines, are responsible for approximately 10% of drug-induced hepatitis cases and must be avoided in liver disease 6

Clinical Bottom Line

Alprazolam does not cause liver cancer. The medication requires dose reduction in patients with pre-existing cirrhosis due to altered pharmacokinetics and should be avoided to prevent hepatic encephalopathy, but there is no carcinogenic risk to the liver from its use 3, 4, 1.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Alprazolam pharmacokinetics in alcoholic liver disease.

Journal of clinical pharmacology, 1984

Guideline

Sedation Management in Liver Cirrhosis and Hepatic Encephalopathy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Pain Management in Hepatobiliary Disease

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

What is the half-life of alprazolam (Xanax)?
Is Alprazolam (a benzodiazepine) a serotonergic agent?
What are the indications, recommended dosing, and side‑effects of Alprax (alprazolam)?
What are the recommended dosing guidelines for alprazolam (Xanax) in adults, including initial dose, titration schedule, maximum dose, adjustments for elderly or hepatic impairment, and recommended duration of therapy?
Is it safe for a patient, particularly the elderly or those with liver dysfunction or impaired renal function, to take 1.5mg of alprazolam (Xanax) at once?
Is sublingual clonidine indicated for treating hypertensive urgency (blood pressure ≥180/110 mm Hg without evidence of acute target‑organ damage)?
What are the indications, contraindications, and preferred oral hypoglycemic agents for an adult with type 2 diabetes mellitus who has not achieved target fasting plasma glucose ≤130 mg/dL or HbA1c ≤7% despite diet, exercise, and weight‑loss measures?
How should I acutely and long‑term treat an adult with aggression and hallucinations, including appropriate haloperidol, olanzapine, lorazepam dosing and considerations for elderly or dementia patients?
Is alcohol consumption a risk factor for hepatocellular carcinoma in adults, especially with heavy intake or existing cirrhosis?
In an adult patient with community‑acquired pneumonia with risk factors for multidrug‑resistant pathogens (CAP‑MR) and normal renal function, can ceftriaxone 2 g IV be extended to a 10‑day course?
What could cause a bitter or metallic taste in a patient taking oral antidiabetic medication, and how should it be managed?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.